Lipella Pharmaceuticals Launches Innovative Bladder Imaging
![Lipella Pharmaceuticals Launches Innovative Bladder Imaging](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Lipella Pharmaceuticals Launches Innovative Bladder Imaging
LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancer.
Novel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and Kidney Diseases.
PITTSBURGH -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer.
LP-20 has completed preclinical and proof-of-concept human trials and is administered via catheter into the bladder. It utilizes advanced MRI technology to identify bladder permeability defects, aiding in the diagnosis of interstitial cystitis and bladder pain syndrome (IC/BPS) and detecting bladder cancer progression to muscle-invasive bladder cancer. Funded, in part by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), LP-20 shows promise as a rapid and cost-effective diagnostic solution for these conditions.
Expert Insights into LP-20
Dr. Michael Chancellor, Chief Medical Officer at Lipella, commented, 'The use of MRI to measure bladder permeability defects offers a potential breakthrough in diagnosing IC/BPS and bladder cancer. This innovative imaging technique addresses significant unmet needs in urology and could greatly enhance patient care. We look forward to sharing our findings with the international scientific community as we continue to develop needed therapeutics for serious diseases.'
Professor Pradeep Tyagi from the University of Pittsburgh Medical Center added, 'LP-20 provides a valuable tool for phenotyping IC/BPS, potentially streamlining patient identification for clinical trials and improving timely access to effective treatments.'
5th International Consultation on Interstitial Cystitis
The 5th International Consultation on Interstitial Cystitis will convene international leaders in the field, featuring special lectures and workshops on pelvic pathology, with proceedings published in a special issue of “The International Journal of Urology,” the official English journal of the Japanese Urological Association.
About LP-20
LP-20 is a dual-component MRI contrast agent designed to identify bladder permeability defects. Administered via catheter, it generates detailed MRI images to diagnose IC/BPS and monitor bladder cancer progression, representing a significant advancement in bladder diagnostics and offering a non-invasive alternative to traditional methods.
About Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and Bladder Cancer
IC/BPS is a challenging condition often diagnosed by exclusion. Current diagnostic methods, including cystoscopy, are limited in differentiating IC/BPS from pelvic floor dysfunction. A new diagnostic tool for bladder permeability could expedite diagnosis and reduce patient suffering. Bladder cancer diagnosis, particularly for muscle-invasive bladder cancer, traditionally relies on invasive procedures like cystoscopy and biopsy. LP-20 aims to complement existing methods with a non-invasive, early-detection imaging technique.
About Lipella Pharmaceuticals Inc.
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering and is trading on Nasdaq under the ticker LIPO. For more information, you can reach them via email.
CONTACT
Jonathan Kaufman
Lipella Pharmaceuticals
Email: Info@Lipella.com
Phone: 1-412-894-1853
Jeff Ramson
PCG Advisory
Email: jramson@pcgadvisory.com
Phone: 646.863.6341
Frequently Asked Questions
What is LP-20?
LP-20 is an MRI contrast agent designed to diagnose interstitial cystitis and bladder cancer.
How does LP-20 work?
It is administered via catheter into the bladder and uses advanced MRI technology to identify bladder permeability defects.
What is interstitial cystitis?
Interstitial cystitis is a painful condition affecting the bladder, often difficult to diagnose and manage.
Who is behind the development of LP-20?
Lipella Pharmaceuticals, a clinical-stage biotech company, is responsible for the development of LP-20.
Where will the findings on LP-20 be presented?
The findings will be presented at the 5th International Consultation on Interstitial Cystitis.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/